Breakthrough Postpartum Depression Pill Shows Significant Promise

A phase III clinical trial conducted by Sage Therapeutics and Biogen has shown promising results for a new drug called Zuranolone, designed to relieve symptoms of postpartum depression. The drug, taken in pill form for multiple days, works by balancing the firing of neurons involved in mood and behavior. In the study, women who received the drug reported significant improvements in their symptoms, while those who received a placebo also saw some improvement. The FDA is expected to decide whether to approve the drug by August 5.